Skip to content

Contact +44 (0) 20 7060 7474 email us

Treatments

U.S. Market for Gastrointestinal Pharmaceuticals

 

Publication Date September 2005
Publisher BCC Research
Product Type Report
Pages 160
ISBN Number not applicable
Product Code BCC00010

Price

£2,885.00
approximately: $4,368 | €3,220

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The gastrointestinal drug market is growing rapidly due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnoses. Although the pharmaceutical industry as a whole has several potential blockbuster drugs in late-stage development, productivity has been lower than expected, particularly in light of higher outlays for research and development. It is troubling for the pharmaceutical industry that new drugs are coming to market in the U.S. at the slowest rate in a decade. This comes despite a three-fold increase in research spending (to $30 billion) and a major overhaul of the U.S. Food and Drug Administration's (FDA) approval process.

Biotechnology products have had a significant impact on overall patient morbidity and mortality. There are several products on the market to treat various gastrointestinal disorders and diseases and many more in clinical trials. These prescription products are expected to greatly impact the market by pushing revenues higher and fueling demands for innovative treatments for gastrointestinal disorders.

This BCC study analyzes therapeutics currently on the market as well as potential products and classes of products that likely will have a significant impact on the future of both the prescription gastrointestinal drug and the over-the-counter gastrointestinal drug markets.

Scope Of Study

The report contains:

  • An overview of gastrointestinal disorders in the U.S.
  • An overview of the gastrointestinal system and brief explanations of disorders, citing risk factors, where applicable; also cites incidence and mortality
  • Discusses current pharmaceutical treatments, market size and market participants in both the prescription and over-thecounter arenas
  • Coverage of potential treatments now in R&D
  • Analysis of market potential with forecasts to 2009
  • A description of the industry in detail, its relationship to the healthcare industry, its participants and future trends.

Report Highlights

  • The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. Rising at an AAGR (average annual growth rate) of 7.3%, the market is expected to reach $22.8 billion in 2009.
  • The prescription market accounted for the largest percentage of sales with approximately 85%, or $13.7 billion in sales in for 2004. This segment is also rising the fastest, with an AAGR of 7.7%.
  • The OTC market accounts for the remaining 15%, or $2.4 billion. Rising at AAGR of 14%, it will represent only 13% of the market in 2009.
  • At approximately 80%, the largest area of market participation for leading competitors is within the prescription drug segment.

Contents

  • Introduction
    • Study Goals And Objectives
    • Reasons For Doing The Study
    • Contributions Of The Study And For Whom
    • Scope And Format
    • Methodology And Information Sources
    • Analyst Credentials
    • Related BCC Reports
    • BCC Online Services
    • Disclaimer
  • Executive Summary
    • Summary Table: U.S. Sales Of Gastrointestinal Presctiption And Otc Drugs At Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Summary Figure: U.S. Sales Of Gastrointestinal Presctiption And Otc Drugs At Manufacturers' Sales Levels, 2002-2009 ($ Millions)
  • Industry Overview
    • Structure And Function Of The Gastrointestinal System
      • Ingestion And Propulsion Of Food
        • Mouth
        • Pharynx
        • Esophagus
      • Digestion And Absorption
        • Mouth
        • Stomach
        • Small Intestines
        • Physiology Of Digestion
      • Elimination
        • Large Intestine
    • Liver, Biliary Tract And Pancreas
      • Liver
      • Bilary Tract
        • Bilirubin Metabolism
      • Pancreas
    • Gastrointestinal Tract Disorders
      • Dysphagia
      • Esophageal And Abdominal Pain
      • Vomiting
      • Intestinal Gas
      • Constipation
      • Diarrhea
    • Gastrointestinal Tract Wall Disorders
      • Gastritis
      • Gastroenteritis
      • Peptic Ulcer Disease
      • Gastric Ulcers
      • Duodenal Ulcers
      • Inflammatory Bowel Disease
      • Ulcerative Colitis
      • Crohn's Disease
      • Enterocolitis
      • Diverticular Disease
    • Gastrointestinal Tract Motility Disorders
      • Irritable Bowel Syndrome
      • Intestinal Obstruction
    • Gastrointestinal Malabsorption Disorders
      • Celiac Disease
      • Tropical Sprue
    • Cancers Of The Gastrointestinal Tract
      • Esophageal Cancer
      • Gastric Cancer
      • Liver Cancer
      • Pancreatic Cancer
      • Small Intestinal Cancer
      • Colonic Polyps And Colon Cancer
    • Demographics
      • Pill-Sized Video Camera
      • Insurance Coverage
      • Use Of Celebrex For Ulcerative Colitis
      • Fast-Acting Acid Pump Antagonists
      • Radio Frequency Identification Technology
      • Branded Vs Otc Proton Pump Inhibitors
      • Pharmaceutical And Health Care Costs
      • Mail Order Trends
  • Prescription Product Segments By Type
    • Antidiarrheals
      • Systemically Acting Antidiarrheals
      • Opium Products
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Antiemetics
      • Locally Acting Antiemetics
      • Centrally Acting Antiemetics
      • Antidopaminergics
      • Anticholinergics
      • Miscellaneous Antiemetics
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Gastrointestinal Cancer Treatments
      • Market Size And Growth
      • Competitive Structure And Market Share
    • H2 Inhibitors
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Laxatives
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Proton Pump Inhibitors
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Anti-Inflammatory
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Other Gastrointestinal Products
      • Antispasmodics
      • Digestants
      • Gastric Acidifiers
      • Pancreatic Enzymes
      • Evacuants
      • Mucosal Protectants
      • Prostaglandins
      • Stimulants
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Total U.S. Prescription Gastrointestinal Market Size And Growth
    • Total U.S. Prescription Gastrointestinal Competitive Analysis
  • Otc Product Segments By Type
    • Antacids
      • Systemic Antacids
        • Sodium Bicarbonate
      • Nonsystemic Antacids
        • Calcium Carbonate
        • Aluminum Products
        • Magnesium Products
        • Combination Products
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Locally Acting Antidiarrheals
      • Adsorbents
      • Intestinal Flora Modifiers
      • Market Size And Growth
      • Competitive Structure And Market Share
    • H2 Inhibitors
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Proton Pump Inhibitors
      • Omeprazole (Prilosec, Proctor & Gamble)
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Other Otc Gastrointestinal Products
      • Antiemetics
        • Locally Acting Antiemetics
        • Centrally Acting Antiemetics
      • Emetics
      • Antiflatulence Products
      • Laxatives
      • Market Size And Growth
      • Competitive Structure And Market Share
    • Total U.S. Otc Gastrointestinal Drug Market Size And Growth
    • Total U.S. Otc Gastrointestinal Drug Competitive Analysis
    • Research And Development
      • Calmactin
      • Canasa
      • Entereg
      • Ptk787
      • Rapinex
      • Tysabri
      • Alicaforsen
      • Cdp-870
      • Methylnaltrexone (MNTX)
      • Opc-6535
      • Orbec
      • Sucampo
      • Renzapride
      • 683699
      • Abt-224
      • Alicaforsen Enema
      • Dextofisopam
      • Ekb-569
      • Gti-2040
      • Pumosetrag
      • Rdp-58
      • Soraprazan
      • Sutent
      • Talnetant
      • Bl-1030
      • Bl-1050
  • Industry Participants By Product Type
    • Company Profiles
      • Astrazeneca
        • History
      • Axcan Pharma Inc.
        • History
      • Centocor Inc
        • History
      • Eisai Inc
        • History
      • Genentech Inc.
        • History
      • Glaxosmithkline
        • History
      • Johnson & Johnson
        • History
      • Mcneil Consumer Healthcare
        • History
      • Merck & Company Inc.
        • History
      • Novartis International Ag
        • History
      • Pfizer Inc.
        • History
      • Procter & Gamble Company
        • History
      • Roche
        • History
      • Sanofi-Aventis
        • History
      • Solvay Pharmaceuticals
        • History
      • Tap Pharmaceuticals Products Inc.
        • History
      • Wyeth
        • History
  • Appendix
    • Company Directory
      • 3m Corporation
      • Abbott Laboratories
      • Acambis Plc
      • Aderis Pharmaceuticals (Discovery Therapeutics)
      • Adolor Corporation
      • Alizyme Plc
      • Allscripts Healthcare Solutions, Inc.
      • Altana Pharma Ag
      • Amarin Corporation
      • Apothecon B.V.
      • Arco Pharmaceuticals
      • Astrazeneca Plc
      • Axcan Pharma Inc.
      • Berlex Laboratories Inc.
      • Bertek (Mylan Laboratories Inc.)
      • Biogen Idec Inc.
      • Biolinerx Ltd.
      • Bioport Corporation
      • Braintree Laboratories Inc.
      • Bristol-Myers Squibb Company
      • Centocor, Inc
      • Chemocentryx Inc.
      • Cytokine Pharmasciences Inc.
      • Dor Biopharma Inc.
      • Eisai Co., Ltd.
      • Elan Corporation Plc
      • Elkins-Sinn Inc.
      • First Horizon Corporation
      • Genaera Corporation
      • Genentech Inc.
      • Genzyme General
      • Glaxosmithkline Plc
      • Glaxosmithkline Consumer Healthcare
      • Hoffman-Laroche Ltd. (ROCHE)
      • Immucell Corporation
      • Inkine Pharmaceutical Company Inc.
      • Isis Pharmaceuticals Inc.
      • Ivax Corporation
      • Janssen Pharmaceutica Products L.P. (Johnson & Johnson)
      • Johnson & Johnson
      • Lorus Therapeutics Inc.
      • Mcneil Consumer & Specialty Pharmaceuticals
      • Medisca Inc.
      • Merck & Co., Inc.
      • Meridian Group International Inc.
      • Monarch Labs
      • Nabi Biopharmaceuticals
      • Novartis Corporation
      • Nps Pharmaceuticals Inc.
      • Otsuka America Pharmaceutical Inc.
      • Perrigo Company
      • Pfizer Inc. (SEARLE)
      • The Procter & Gamble Company
      • Prodigene Inc.
      • Progenics Pharmaceuticals Inc.
      • Protein Design Labs Inc.
      • Raven Biotechnologies Inc.
      • Reliant Pharmaceuticals Inc.
      • Roxane Laboratories Inc.
      • Salix Pharmaceuticals Ltd.
      • Sanofi-Aventis
      • Santarus Inc.
      • Schering Ag
      • Schwarz Pharma Ag
      • Serono S.A.
      • Shire Pharmaceuticals Group Plc
      • Solvay S.A.
      • Sucampo Pharmaceuticals Inc.
      • Swiss Agency For Therapeutic Products (SWISSMEDIC)
      • Tanox Inc.
      • Tap Pharmaceutical Products Inc.
      • Targacept Inc.
      • Theravance Inc.
      • Ucb Pharma Inc.
      • Unimed Pharmaceuticals Inc.
      • Vela Pharmaceuticals Inc.
      • Watson Pharmaceuticals, Inc.
      • Wyeth (Whitehall-Robins Healthcare Inc.)
      • Xoma Ltd.
      • Yamanouchi Pharma Ltd.
  • List Of Figures
    • Summary Table: U.S. Sales Of Gastrointestinal Presctiption And Otc Drugs At Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 1 Causes Of Diarrhea
    • Table 2 Common Causes Of Gastritis
    • Table 3 U.S. Estimated Incidence/Prevalence/Mortality Of Selected Gastrointestinal Conditions
    • Table 4 U.S. Population By Selected Age Groups And By Percent Of Total Population, 2002-2030 (THOUSANDS)
    • Table 5 Patent Expiration For Selected Prescription Gastrointestinal Drugs 2005-2013
    • Table 6 Marketed Antidiarrheal Products
    • Table 7 Product Revenues Of U.S. Prescription Antidiarrheals At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 8 U.S. Prescription Antidiarrheals Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 9 Marketed Antiemetic Products
    • Table 10 Product Revenues Of U.S. Prescription Antiemetics At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 11 U.S. Prescription Antiemetic Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 12 Marketed Gastrointestinal Cancer Products
    • Table 13 Product Revenues Of U.S. Prescription Gastrointestinal Cancer Drugs At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 14 U.S. Prescription Gastrointestinal Cancer Drugs Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 15 Marketed H2 Inhibitors Products
    • Table 16 Product Revenues Of U.S. Prescription H2 Inhibitors At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 17 U.S. Prescription H2 Inhibitors Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 18 Marketed Laxative Products
    • Table 19 Product Revenues Of U.S. Prescription Laxatives At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 20 U.S. Prescription Laxatives Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 21 Marketed Proton Pump Inhibitor Products
    • Table 22 Product Revenues Of U.S. Prescription Proton Pump Inhibitors At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 23 U.S. Prescription Proton Pump Inhibitors Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 24 Marketed Inflammatory Products
    • Table 25 Product Revenues Of U.S. Prescription Gastrointestinal Inflammatory Agents At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 26 U.S. Prescription Gastrointestinal Inflammatory Agents Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 27 Marketed Antispasmodic Products
    • Table 28 Marketed Digestant Products
    • Table 29 Marketed Evacuants Products
    • Table 30 Marketed Mucosal Protectant Products
    • Table 31 Marketed Prostaglandin Products
    • Table 32 Marketed Stimulant Products
    • Table 33 Product Revenues Of U.S. Prescription Other Gastrointestinal Drugs At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 34 U.S. Prescription Other Gastrointestinal Drug Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 35 Market Size Of U.S. Prescription Gastrointestinal Disorder Treatment Markets By Type At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 36 Total Manufacturers Sales And Market Share Of Prescription Gastrointestinal Disorder Treatments At U.S. Manufacturers' Sales Levels, 2004 ($ Millions)
    • Table 37 Marketed Otc Antacid Products
    • Table 38 Product Revenues Of U.S. Otc Antacids At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 39 U.S. Otc Antacid Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 40 Marketed Otc Antidiarrheal Products
    • Table 41 Product Revenues Of U.S. Otc Antidiarrheals At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 42 U.S. Otc Antidiarrheals Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 43 Marketed Otc H2 Inhibitors Products
    • Table 44 Product Revenues Of U.S. Otc H2 Inhibitors At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 45 U.S. Otc H2 Inhibitor Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 46 Marketed Otc Proton Pump Inhibitor Products
    • Table 47 Product Revenues Of U.S. Otc Proton Pump Inhibitors At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 48 U.S. Otc Proton Pump Inhibitor Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 49 Marketed Otc Antiemetics Products
    • Table 50 Marketed Otc Emetic Products
    • Table 51 Marketed Otc Antiflatulence Products
    • Table 52 Marketed Otc Laxative Products
    • Table 53 Product Revenues Of U.S. Otc Other Gastrointestinal Drugs At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 54 U.S. Otc Other Gastrointestinal Drugs Manufacturers' Revenues And Market Share, 2004 ($ Millions, %)
    • Table 55 Market Size Of U.S. Gastrointestinal Disorder Treatment Market By Type At U.S. Manufacturers' Sales Levels, Through 2009 ($ Millions)
    • Table 56 Manufacturers Market Share Of Total Otc Gastrointestinal Disorder Treatments At U.S. Manufacturers' Sales Levels, 2004 ($ Millions, %)
    • Table 57 Gastrointestinal Disorder Treatments In Development
    • Table 58 Gastrointestinal Disorder Treatment Manufacturers By Type, 2004
  • List Of Figures
    • Summary Figure: U.S. Sales Of Gastrointestinal Presctiption And Otc Drugs At Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 1 U.S. Population By Selected Age Groups, 2002-2030 (THOUSANDS)
    • Figure 2 U.S. Population Selected Age Groups By Percent Of Total Population, 2002-2030 (%)
    • Figure 3 Product Revenues Of U.S. Prescription Antidiarrheals At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 4 U.S. Prescription Antidiarrheals Manufacturers' Market Share, 2004 (%)
    • Figure 5 Product Revenues Of U.S. Prescription Antiemetics At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 6 U.S. Prescription Antiemetics Manufacturers' Market Share, 2004 (%)
    • Figure 7 Product Revenues Of U.S. Prescription Gastrointestinal Cancer Drugs At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 8 U.S. Prescription Gastrointestinal Cancer Drugs Manufacturers' Market Share, 2004 (%)
    • Figure 9 Product Revenues Of U.S. Prescription H2 Inhibitors At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 10 U.S. Prescription H2 Inhibitors Manufacturers' Market Share, 2004 (%)
    • Figure 11 Product Revenues Of U.S. Prescription Laxatives At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 12 U.S. Prescription Laxatives Manufacturers' Market Share, 2004 (%)
    • Figure 13 Product Revenues Of U.S. Prescription Proton Pump Inhibitors At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 14 U.S. Prescription Proton Pump Inhibitors Manufacturers' Market Share, 2004 (%)
    • Figure 15 Product Revenues Of U.S. Prescription Gastrointestinal Inflammatory Agents At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 16 U.S. Prescription Gastrointestinal Inflammatory Agents Manufacturers' Market Share, 2004 (%)
    • Figure 17 Product Revenues Of U.S. Prescription Other Gastrointestinal Drugs At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 18 U.S. Prescription Other Gastrointestinal Drug Manufacturers' Market Share, 2004 (%)
    • Figure 19 Market Size Of U.S. Prescription Gastrointestinal Disorder Treatment Market By Type At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 20 Manufacturers Market Share Of Total Prescription Gastrointestinal Disorder Treatments At U.S. Manufacturers' Sales Levels, 2004 (%)
    • Figure 21 Product Revenues Of U.S. Otc Antacids At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 22 U.S. Otc Antacid Manufacturers' Market Share, 2004 (%)
    • Figure 23 Product Revenues Of U.S. Otc Antidiarrheals At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 24 U.S. Otc Antidiarrheals Manufacturers' Market Share, 2004 (%)
    • Figure 25 Product Revenues Of U.S. Otc H2 Inhibitors At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 26 U.S. Otc H2 Inhibitor Manufacturers' Market Share, 2004 (%)
    • Figure 27 Product Revenues Of U.S. Otc Proton Pump Inhibitors At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 28 Product Revenues Of U.S. Otc Other Gastrointestinal Drugs At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 29 U.S. Otc Other Gastrointestinal Drugs Manufacturers' Market Share, 2004 (%)
    • Figure 30 Market Size Of U.S. Gastrointestinal Disorder Treatment Market By Type At U.S. Manufacturers' Sales Levels, 2002-2009 ($ Millions)
    • Figure 31 Total Manufacturers Market Share Of Otc Gastrointestinal Disorder Treatments By Revenues At U.S. Manufacturers' Sales Levels, 2004 (%)